Please enable Javascript
Leah Lawrence
Leah Lawrence is a freelance health writer and editor based in Delaware.
Articles by Leah Lawrence
How Can We Challenge the Status Quo in Myeloma Research?
Leah Lawrence
Latest Issue
|
September 20, 2023
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Read More
First-Line Selinexor, Ruxolitinib Shows Ongoing Promise for Myelofibrosis
Leah Lawrence
Meeting News
|
September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Read More
Luspatercept Improved Anemia, Transfusion Burden in Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Read More
Pacritinib Spleen Response Yielded OS Benefit in Cytopenic Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Read More
Event-free Survival at 24 Months in MCL Yielded Expected OS of General Population
Leah Lawrence
Mantle Cell Lymphoma
|
September 10, 2023
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Read More
Questions Remain About Role of Hypoxia Related to NHL CAR T-cell Therapy
Leah Lawrence
Meeting News
|
September 10, 2023
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
Read More
Data on T-cell Exhaustion Support Earlier Use of T-cell-based Therapies in Splenic MZL
Leah Lawrence
Meeting News
|
September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Read More
Shorter Duration Induction Venetoclax Feasible for Older, Unfit AML
Leah Lawrence
Acute Lymphoblastic Leukemia
|
September 6, 2023
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Read More
T-Cell ALL Overall Survival Differed by Ethnicity, Small Study Showed
Leah Lawrence
Meeting News
|
September 6, 2023
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
Read More
Mosunetuzumab Showed Durable Responses for Relapsed or Refractory Follicular Lymphoma
Leah Lawrence
Indolent B-Cell Lymphoma
|
September 1, 2023
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
Read More
What’s Next for MRD in Myeloma?
Leah Lawrence
Myeloma
|
May 31, 2023
Researchers discuss how monitoring MRD in peripheral blood can aid in myeloma management.
Read More
Target on the Move
Leah Lawrence
Myelodysplastic Syndromes
|
April 12, 2023
Novel targets are under investigation in several types of hematologic malignancies.
Read More
An Unclear Path: What’s the Best Route After CAR-T Failure in B-Cell Lymphoma?
Leah Lawrence
Aggressive B-Cell Lymphoma
|
February 7, 2023
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Read More
Bispecific Antibodies: New Options
Leah Lawrence
Print
|
January 13, 2023
With more bispecific antibodies in development for hematologic malignancies, physicians must determine how best use them.
Read More
Clinicians Tackle the Challenges of MCL
Leah Lawrence
Print
|
December 22, 2022
Experts discuss areas of progress and where more work is needed to establish a standard of care in mantle cell lymphoma.
Read More
ALL Prognosis in Elderly Patients Has Shown Some Improvement
Leah Lawrence
Meeting News
|
December 20, 2022
There has been an improvement in the prognosis of older patients diagnosed with acute lymphoblastic leukemia.
Read More
Study Examines Resistance to Venetoclax Plus Gilteritinib in R/R AML
Leah Lawrence
Acute Myeloid Leukemia
|
December 19, 2022
Researchers have identified possible resistance mechanisms to gilteritinib plus venetoclax in patients with R/R AML.
Read More
MRD Status Linked with Outcomes in Venetoclax-Treated NPM1-Mutated AML
Leah Lawrence
Acute Myeloid Leukemia
|
December 19, 2022
Molecular MRD was strongly prognostic in patients with NPM1-mutated AML who received venetoclax-based non-intensive therapy.
Read More
MRD Profiling Study Reveals Transcriptional Divergence After Transplant for Myeloma
Leah Lawrence
Myeloma
|
December 10, 2022
Use of drugs with alternative modes of action may be needed to overcome persistent MRD positivity in myeloma.
Read More
Lymphoma Survivors at Increased Risk for Secondary Primary Malignancies
Leah Lawrence
Meeting News
|
December 10, 2022
Survivors of lymphoma are at risk for the development of a second primary malignancy, including new lymphomas.
Read More
Load More